Solta Medical Launches the Clear + Brilliant Touch Laser

Solta Medica*l notes the Clear + Brilliant Touch Laser delivers a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths.

By seamlessly switching between two wavelengths with the Original and Perméa® handpieces, physicians can now more easily deliver a more complete treatment during a single appointment.

“The new innovative features of the Clear + Brilliant® Touch laser are designed to make the system easier and more convenient to use. Aesthetic providers can now more efficiently offer patients a complete treatment using two wavelengths by seamlessly switching between the Original and Perméa® handpieces during one appointment. We believe physicians and their patients will experience a real advantage with the new Clear + Brilliant® Touch laser,” said Tom Hart, global vice president, Solta Medical. “As pioneers in the aesthetic market, Solta Medical has continued to evolve the Clear + Brilliant® technology to improve upon the efficiency and convenience that physicians and their patients have come to expect from Solta Medical.”

In addition to offering easy access to both the Original and Perméa® handpieces in the compact system, the Clear + Brilliant® Touch laser also includes a user-friendly touchscreen, a simple training mode to simulate treatment without emitting laser energy and a smart charting assistant that automatically tracks treatment progress with the ability to export patient treatment charts.

“The Clear + Brilliant® laser is an easy-to-use and transportable system that has been a mainstay in my practice for years. The new system, the Clear + Brilliant® Touch laser offers even more versatility,  for my patients. Having the option to use both wavelengths seamlessly during one appointment will be a welcome addition to my practice and to my patients,” said Jeffrey S. Dover, M.D., FRCPC, a board-certified dermatologist in Boston, MA.

*Solta Medical, part of the Ortho Dermatologics business of Bausch Health Companies Inc., is a global leader in the medical aesthetics market that helps drive revenue growth to aesthetic practices by providing innovative and effective skin rejuvenation and body contouring solutions. Solta Medical’s vision is to develop and support trusted aesthetic brands that provide value and lasting growth to physicians and patients. These include the Thermage® RF systems, Fraxel® laser, Clear + Brilliant® laser and VASER® ultrasonic systems. More than six million procedures have been performed with Solta Medical’s portfolio of products around the world.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.